According to a company spokesperson, the patent-pending ‘NovoSerum’ is a cell-free, non-stem cell complex derived from purified human umbilical cord serum that triggers fibroblasts to increase collagen production to stop, slows down and reverse skin damage in thirty days.
“The complex features 12 antioxidants, four neuro-peptides, six collagen and matrix stimulants, eight anti-inflammatory agents and 24 moisturizers and emollients that repair and restore age lost cellular mechanics to restore natural collagen and enhance the skin matrix."
Tried and tested
Manufactured by a US cryobanking facility, the umbilical cord serum is said to be comprised of human growth factors, 350 molecules, proteins, cell signalers, nutrients, peptides, and vitamins.
The US Food and Drug Administration (FDA) is further said to have processed the serum to remove cellular material to retain the peptides and nutrients before the product was feasible to go to market globally.
Trials carried out by Novo Solutions are said to have reported results of "94 per cent of people experiencing more youthful looking skin, 79 found a decrease in under eye puffiness while 73 per cent saw a decrease in wrinkles and fine lines."
Anti-ageing sector faring well…
A recent report carried out by Mintel found that the Western markets (US, UK and France) account for the most anti-ageing skin care product launches between 2009 and 2011 in comparison to Japan and China. In light of this, cosmetic companies have been going above and beyond to come up with unique ingredients to compete in the vast segment.
Earlier in the year, BASF Beauty Care Solutions revealed it had funded a study that found an extract of the common yarrow plant in the Northern hemisphere to increase epidermal thickness and improve the appearance of wrinkles and pores.
Then, researchers had evaluated the effect of A. millefolium extract on the expression pattern of various epidermal differentiation markers ex vivo in normal human skin biopsies using quantitative image analysis.